Protection against feline immunodeficiency virus using replication defective proviral DNA vaccines with feline interleukin-12 and-18

A molecular clone of the Glasgow-8 isolate of FIV (FIVGL8) was rendered replication defective by an in-frame deletion in either reverse transcriptase (DeltaRT) or integrase (DeltaIN) genes for use as DNA vaccines. To test the ability of these multi-gene vaccines to protect against two feline immunodeficiency virus (FIV) isolates of differing virulence, cats were immunized using either DNA vaccine alone or co-administered with interleukin-12 (IL- 12) and/or interleukin- 18 (IL- 18) cytokine DNA. Animals were challenged sequentially with FIV-Petaluma (FIVPET) an FIV isolate of relatively low virulence and subsequently with the more virulent FIVGL8. A proportion of vaccinates (5/18 DeltaIN and 2/12 DeltaRT) were protected against primary challenge with FIVPET. Five of the vaccinated-protected cats were rechallenged with FIVPET; four (all DeltaIN) remained free of viraemia. whilst all naive controls became viraemic. Following subsequent challenge with the more virulent FIVGL8 these four vaccinated-protected animals all became viraemic but showed lower proviral loads than naive cats. This study suggests that while our current DNA vaccines may not produce sterilizing immunity against more virulent isolates of FIV, they may nevertheless significantly reduce the impact of infection. (C) 2002 Elsevier Science Ltd. All rights reserved.